Cara Therapeutics, Inc. CARA) Q2 2021 Earnings Call Transcript

Cara Therapeutics, Inc. (NASDAQ: CARA) Q2 2021 earnings call dated Aug. 09, 2021

Corporate Participants:

Cole Herlitz-Ferguson — Investor Relations

Derek Chalmers — Chief Executive Officer, President, and Director

Thomas Reilly — Chief Financial Officer

Analysts:

Jessica Fye — J.P. Morgan Securities, LLC — Analyst

Chris Howerton — Jefferies LLC — Analyst

David Amsellem — Piper Sandler & Co. — Analyst

Jason Gerberry — Bank of America Merrill Lynch — Analyst

Jack Padovano — Stifel Financial Corp. — Analyst

Oren Livnat — H.C. Wainwright & Co. — Analyst

Presentation:

Operator

Good afternoon and welcome to the Cara Therapeutics Second Quarter 2021 Financial Results Conference Call. [Operator Instructions] Please be advised that this call is being recorded at Cara’s request.

I would now like to turn the call over to the Cara team. Please proceed.

Cole Herlitz-Ferguson — Investor Relations

Good afternoon. This is Cole Herlitz-Ferguson with Stern Investor Relations and welcome to Cara Therapeutics’ second quarter 2021 financial results and update conference call. The news release became available just after 4:00 PM today and can be found on our website at www.caratherapeutics.com. You may also listen to a live webcast and replay of today’s call on the Investors section of the website. Before we begin, let me remind you that statements made on today’s call regarding matters that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.

Examples of these forward-looking statements, include statements concerning the expected timing of the data readouts from the company’s planned and ongoing clinical trials, the potential results of ongoing clinical trials, timing of future regulatory and development milestones for the company’s product candidates, including the company’s projected timeline for FDA review and potential approval and commercial launch of KORSUVA Injection for dialysis dependent CKD-aP, the expected timeline for conducting meetings with the FDA concerning the company’s product candidates, including Oral KORSUVA for NDD CKD-aP and AD-aP, the potential for the company’s product candidates to be alternatives in the therapeutic areas investigated, the potential impact of COVID-19 on the company’s clinical development and regulatory timelines and plans and the company’s expected cash reach.

Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Risks are described more fully in Cara Therapeutics’ filings with the Securities and Exchange Commission, including the Risk Factors section of the company’s most recent Annual Report on Form 10-K and its other documents subsequently filed or furnished to the Securities and Exchange Commission. All forward-looking statements made in today’s call speak only as of the date in which they were made. Cara Therapeutics undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. Participating on today’s call are Dr. Derek Chalmers, Cara’s President and CEO; and Mr. Thomas Reilly, Cara’s Chief Financial Officer.

I’ll now turn the call over to Dr. Chalmers.

Derek Chalmers — Chief Executive Officer, President, and Director

Okay. Thank you Cole, and good afternoon everybody and thanks for joining us today on the call. We have continued to make significant progress across our KORSUVA development pipeline in the second quarter of this year with our NDA for our lead product candidate KORSUVA Injection for the treatment of moderate-to-severe pruritus and hemodialysis patients under priority review. Our interactions with the FDA have progressed efficiently and on schedule and through the completion of our late-cycle review, we remain on track for an expected PDUFA target action date of August 23 of this year. In addition, we continue to make important progress across our Oral KORSUVA pipeline programs.

To that end in Q2 of this year, we reported top line results from our Phase II KARE dose ranging clinical trial of Oral KORSUVA for the treatment of moderate-to-severe pruritus in atopic dermatitis patients. Based on pre-specified analysis of that data set we’ve identified the appropriate patient population and dose strengths to move forward and depending the outcome of discussions with the FDA later this quarter and to initiate a Phase III registration program in mild-to-moderate atopic dermatitis patients by year end. We also plan to meet with the agency in the coming months to discuss the appropriate pre-dialysis CDK patient population to move forward to Phase III in that program.

And we continue to enroll patients in our ongoing trials in both PBC and notalgia paresthetica with the aim of establishing KORSUVA’s efficacy across a range of patient pathologies for treatment of chronic pruritus remains a significant unmet need. So the remainder of 2021 is shaping up to be truly transformative for the company with the potential approval and commercial launch of the first therapy for the treatment of pruritus and hemodialysis patients and potential advancement of Oral KORSUVA into registration trials. So with that, now let me provide you with some additional details across our main pipeline programs beginning with our most advanced program, KORSUVA Injection.

Following the FDA’s acceptance of our NDA filing with priority review in the first quarter of this year, our dialogue with the agency has progressed well. And without any review delays, based on the outcome of our late-cycle review last quarter, we currently do not anticipate any manufacturing and inspection delays and we expect the agency to meet their PDUFA target action date of August 23 of this year. With that in mind, we remain focused along with our U.S. commercialization partner Vifor Pharma for the commercial launch of KORSUVA Injection in the second half of this year.

As a reminder, based on Vifor’s established U.S. nephrology sales force and their deep-rooted relationships with both large and small U.S. dialysis organizations, Cara executed a strategic license agreement with Vifor Pharma in the fourth quarter of last year for the commercialization of KORSUVA Injection in U.S. dialysis clinics under a Cara 60%, Vifor 40% profit share arrangement. And we firmly believe that will support increased launch momentum and adoption of KORSUVA in the U.S. market if approved. The financial considerations of the Vifor agreement contributes significantly to the current strength of our balance sheet.

Based on the terms of the license, the company will be eligible to receive an additional $50 million common stock investment upon U.S. regulatory approval of KORSUVA Injection and post launch be eligible to receive payments of up to $240 million in U.S. sales-based commercial milestones. On KORSUVA Injection reimbursement activity, our ongoing interactions with CMS have been productive and we plan to file both our TDAPA and HCPCS applications later in Q3, again assuming KORSUVA Injection approval.

Turning to ex-U.S. commercialization planning; we were also very pleased to announce earlier this year that the European Medicines Agency accepted the MAA for difelikefalin injection for the treatment of pruritus associated with chronic kidney disease in hemodialysis patients. The EMA will review the application under the centralized marketing authorization procedure and under our 2018 license agreement Vifor Fresenius will be responsible for commercialization of KORSUVA Injection across European territories with Cara eligible to receive tiered double-digit royalty payments based on annual net sales and up to $440 million in tiered commercial milestones, all of which are sales related. The EMA is expected to render their decision in the second quarter of 2022.

Turning now to progress on our Oral KORSUVA pipeline; we recently announced top line results from the KARE Phase II dose-ranging trial of Oral KORSUVA for the treatment of moderate-to-severe pruritus in atopic dermatitis patients. This trial, you’ll recall was a randomized double-blind placebo controlled study designed to evaluate the efficacy and safety of Oral KORSUVA in 401 adult subjects with atopic dermatitis. Patients were stratified across the treatment groups by disease severity with 64% approximately of patients characterized by mild-to-moderate atopic dermatitis and approximately 36% of patients characterized by moderate-to-severe atopic dermatitis.

Patients were randomized to three tablet strengths of Oral KORSUVA 0.2, 0.5 and 1 milligram taken BID versus placebo for 12 weeks followed by 4 weeks of active extension. In pre-specified analysis, a statistically significant change in the primary efficacy endpoint was observed in the mild-to-moderate, that is BSA less than 10% patient population, which was evident at week 1 and sustained through the treatment period. In addition, a statistically significant improvement was also observed in the registration endpoint, a 4-point responder analysis in the mild-to-moderate patient population with 32% of KORSUVA treated patients achieving a greater than 4 point reduction in NRS at week 12 versus 19% in the placebo group.

So these KARE results have provided key information related to the defined patient group, that is mild-to-moderate, and active dose range and an effect size on the registration 4-point responder endpoint from which to design appropriately powered Phase III trials. So with that data in hand and pending the outcome of our scheduled end of Phase II meeting with the FDA, we aim to initiate our first Oral KORSUVA Phase III program in mild-to-moderate atopic dermatitis patients by year end 2021. We also plan to present additional data and additional analysis from the KARE trial at upcoming medical meetings later this year.

So to step back and think a little in terms of ultimate potential positioning of Oral KORSUVA and the atopic dermatitis treatment landscape, it’s clear that while pruritus is recognized as a definitive and indeed the most burdensome symptom of atopic dermatitis, therapeutic development to-date in this area has focused on pro-inflammatory pathways rather than pruritogenic pathways. And there is a particular treatment gap amongst mild-to-moderate atopic dermatitis patients, which is approximately 80% of the AD population where topical therapies do not adequately address chronic pruritus and systemic immunomodulatory agents are not available. So based on its observed profile from our KARE dataset, we believe that Oral KORSUVA may provide clinical benefit for these patients and provide a systemic anti-pruritic therapeutic option were non-presently exists.

So moving on to our program in pre-dialysis CKD patients with moderate-to-severe pruritus, we recently conducted an end of Phase II meeting with the FDA with the goal of defining a Phase III program in pre-dialysis patients, which would allow us to leverage the substantial clinical efficacy and safety data set we’ve compiled with KORSUVA Injection and hemodialysis patients. The FDA has indicated the viability of Stage 5 pre-dialysis CKD patients as a population for a Phase III program and also indicated the potential to use the data from our previous trials of KORSUVA Injection in dialysis patients to support an approval based on a single Phase III clinical trial.

We are currently gathering more data related to pruritus incidents and severity in pre-dialysis CKD patients and aim to meet with the agency in the fourth quarter of this year to further define a viable patient population for inclusion and a Phase III program. Finally, to our ongoing Phase II trials in Primary Biliary Cholangitis and notalgia paresthetica; before I get to that, I would like to remind everyone that due to the ongoing COVID-19 pandemic and in accordance with the FDA’s updated guidance for conducting clinical trials, we’ve implemented numerous clinical and operational measures to prioritize the health and most importantly, the safety of patients, our employees and study investigators and minimize potential disruptions to our ongoing clinical studies.

Pruritus is a common symptom of cholestatic liver diseases. 20% to 30% of these patients overall experience pruritus with that number rising to approximately 70% of patients with Primary Biliary Cholangitis. Our 16 week Phase II trial is designed to assess the safety and efficacy of a 1 milligram tablet strength of Oral KORSUVA taken twice daily versus placebo and PBC patients with moderate-to-severe pruritus. The primary endpoint is the change from baseline and the weekly mean of the daily 24 hour Worst Itch-NRS score at week 16. We now expect to report topline data from this study in the first half of 2022 due to delays in site initiations and patient enrollment resulting from the ongoing COVID-19 pandemic.

Finally, with the goal of further establishing the broad anti-pruritic applicability of KORSUVA across patient populations with underlying pathologies, earlier this year we initiated a Phase II proof of concept trial of Oral KORSUVA for the treatment of moderate to severe pruritus in patients suffering from notalgia paresthetica, a neuropathic disorder characterized by chronic pruritus in the upper to middle back. The Phase II multi-center, randomized, double-blind, placebo-controlled 8-week study is designed to evaluate the efficacy and safety of Oral KORSUVA in approximately 120 subjects with notalgia paresthetica randomized to receive Oral KORSUVA 2 mgs twice daily versus placebo for 8 weeks, followed by a 4 week active extension period.

Primary efficacy endpoint was a change from baseline, the weekly mean of the daily 24 hour Worst Itch-NRS score at week 8 of the treatment period. And I’m pleased to note today that this trial has now passed the 50% enrollment mark and based on our current recruitment rates we expect full enrollment in this trial by the end of this year. So overall, our progress through Q2 and recent months has laid the foundation for a very significant second half of ’21. We very much look forward to the expected PDUFA target action date later this month for KORSUVA Injection as potentially the first FDA approved therapeutic for the treatment of pruritus in hemodialysis patients.

And we are well prepared, along with our partner Vifor Pharma for a commercial launch of KORSUVA Injection in the second half of this year. With a strong balance sheet, we’re well-positioned to support our goal of initiating our first Phase III program with Oral KORSUVA in mild-to-moderate AD patients by year-end as well as continue to progress our ongoing oral programs in CKD and PBC in notalgia paresthetica patients. And we’ll be updating you in all of the progress across these programs in the coming weeks and months.

So with that, I’ll now turn it over to Tom to detail the financial results for this quarter.

Thomas Reilly — Chief Financial Officer

Thank you, Derek. As a reminder, the full financial results for the second quarter 2021 can be found in our press release issued today after the market closed. Cash, cash equivalents and marketable securities as of June 30, 2021 totaled $207.4 million compared to $251.5 million at December 31, 2020. The decrease in the balance primarily resulted from cash used in operating activities of $44.7 million partially offset by proceeds of $1 million from the exercise of stock options. For the second quarter 2021, net loss was $30.7 million, or $0.61 per basic and diluted share compared to a net loss of $25.1 million or $0.54 per basic and diluted share for the same period in 2020.

There was no revenue for the three months ended June 30, 2021. This compared to the $5.6 million during the same period of 2020. The company recognized $5.1 million of license and milestone revenue during the second quarter of 2020, $4.5 million of which related to our license agreement with VFMCRP and $0.6 million of which related to achievement of the development milestone related to our license agreement with CKD Pharmaceutical Cop. The company also recognized $0.5 million of clinical compound revenue in the second quarter of 2020 to Maruishi Pharmaceutical Company and VFMCRP. Research and development expenses were $25.2 million for the three months ended June 30, 2021 compared to $26.1 million in the same period of 2020.

The lower R&D expenses in 2021 were principally due to a net decrease in costs associated with clinical trials and stock compensation expense partially offset by a $10 million milestone earned by Enteris Biopharma during the three months ended June 30, 2021. General and administrative expenses were $5.7 million for the three months ended June 30, 2021. This compared to $5.4 million in the same period of 2020. The higher G&A expenses in 2021 were principally due to an increase in payroll costs, commercial costs and legal fees, partially offset by a decrease in stock compensation expense. Other income net was $0.1 million for the three months ended June 30, 2021 compared to $0.6 million in the same period of 2020.

The decrease in other income net was primarily due to a decrease in interest income resulting from a lower yield on the company’s portfolio of investments in the 2021 period. Now, turning to our finance guidance, based on timing, expectation and projected costs for current clinical development plans, Cara expects that its existing unrestricted cash and cash equivalents and available for sale marketable securities as of June 30, 2021 will be sufficient to fund our currently anticipated operating expenses and capital expenditures into 2023 without giving effect to any potential milestone payments or potential product revenue under existing collaborations.

I will now turn the call back over to the operator for Q&A.

Questions and Answers:

Operator

Thank you. [Operator Instructions] We have your first question from Jessica Fye with J.P. Morgan. Your line is open.

Jessica Fye — J.P. Morgan Securities, LLC — Analyst

Thank you for taking the questions. Firstly, can you talk about the timing for the recently announced API Supply Agreement with PPL? Is this typical days close to the PDUFA and does it affect the NDA in any way?

Derek Chalmers — Chief Executive Officer, President, and Director

Yes, hi, thanks. Thanks for the question. No, it’s a standard commercial API Supply Agreement, does not affect the PDUFA date or review of the NDA in any way whatsoever.

Jessica Fye — J.P. Morgan Securities, LLC — Analyst

Okay. And for the oral program in non-dialysis setting, when do you expect to initiate the Phase III program? Would you wait for the FDA decision for inclusion of earlier stage patients in the trial, or would you start irrespective of that?

Derek Chalmers — Chief Executive Officer, President, and Director

No. So presently we’re gathering both patient data and we have physician research underway in relation to incidents and severity of pruritus in pre-dialysis CKD patients. And once we’ve gathered that information fully, our plan is to engage with the FDA probably in Q4 of this year to get an agreement on a viable pre-dialysis CKD population for inclusion in that Phase III program. So it’s likely that that would initiate early in 2022.

Jessica Fye — J.P. Morgan Securities, LLC — Analyst

Got it. Thank you.

Derek Chalmers — Chief Executive Officer, President, and Director

Thank you very much.

Operator

We have your next question from Chris Howerton with Jefferies. Your line is open.

Chris Howerton — Jefferies LLC — Analyst

Great. Congratulations. Very exciting times for Cara. Thanks for taking the questions.

Derek Chalmers — Chief Executive Officer, President, and Director

Thank you.

Chris Howerton — Jefferies LLC — Analyst

Yeah, of course. So for the — I guess for the — maybe following up on the added criteria for the Oral CKD program, was the sense that the FDA did not feel like there was unmet need in less severe patients in Stage 5 or was it simply the case where there was insufficient information to make that kind of judgment call? I guess is one question. And then the second question I had, Derek, was related to the atopic dermatitis program. I think I feel like you described this last time, but if you could just remind us what it is that you’d like to align with the FDA with respect to that program? Is there is something — in addition to what you’ve described to us here in terms of going after the mild-to-moderate in the dose ranges that you believe to be active?

Derek Chalmers — Chief Executive Officer, President, and Director

All right, thanks, Chris. Let’s start with your CKD question. I feel it’s the latter of your two options in relation to the FDA. There’s a lack of information presently in relation to pruritus incidence and the severity of that in earlier stage CKD patients relatively speaking towards in relation to Stage 5, which is obviously the final stage prior to hemodialysis. So with that in mind, our view has been, we are empirically developing that information in collaboration with the National Kidney Foundation.

We’re running patient research. We’re also running physician research and we aim to get if you like, more recent or more up-to-date information we can use there to define the breadth of the pruritus issue in the pre-dialysis CKD population that we can then use as a basis for a discussion with the FDA in relation to where we define that population for inclusion in a Phase III. So it’s really filling the gap in terms of lack of available information, if you like, real-time in those earlier populations that we have underway. So that’s the progress there.

And as I said, we aim to have that meeting with the FDA in the coming months to define that. In terms of AD, I’m not quite sure what you’re getting out there. Our view on the AD program as we’re looking for a label to treat moderate-to-severe pruritus, specifically within mild-to-moderate AD patients that are need of systemic anti-pruritic therapy. And our view there is that based on our Phase II data we certainly see an appropriate profile for monotherapy that we can significantly reduce pruritus as a rapid onset. We have a very attractive safety profile for the drug. And so that’s the basis of our end of Phase II briefing book and we’d like to see that program progress with the agents.

Chris Howerton — Jefferies LLC — Analyst

Got it. Okay. So, it’s simply — got it, okay. Alignment on trial design in the final regulatory path.

Derek Chalmers — Chief Executive Officer, President, and Director

Exactly, exactly. You know how that goes.

Chris Howerton — Jefferies LLC — Analyst

Okay. Always crystal clear. I guess, maybe if you wouldn’t mind, just a quick follow-up to maybe my previous question. Is there – do you have — what have you disclosed about your view of the epidemiology of the Stage 5 patients that would experience moderate-to-severe pruritus?

Derek Chalmers — Chief Executive Officer, President, and Director

Well, based on the data as I said, there is some published did out there you could find Chris. There’s a DOPS analysis, two DOPS surveys looking at severity and frequency in pre-hemodialysis CKD patients and they’re certainly clear of the severity of the pruritus increases with the severity of CKD disease. What we are looking at and beginning to see in our analysis is a somewhat similar frequency in Stage 4 and Stage 5, particularly later Stage 4. And as you know the dividing lines between those are somewhat arbitrary. It seems clear that physicians really regard the patient in terms of late-stage versus earlier around these defined threshold versus EGFR definitions. And from their analysis, and their feedback it’s clear that they regard pruritus as a significant issue in late stage pre-dialysis CKD patients. So we’re just trying to put some parameters around that population so we can define that more accurately and then talk to the agency again on what should be included.

Chris Howerton — Jefferies LLC — Analyst

Okay. No, that’s very clear. I appreciate the added color. Okay, but thanks Derek. Appreciate you answering the questions.

Derek Chalmers — Chief Executive Officer, President, and Director

Thank you. Thanks for the questions.

Operator

We have your next question from David Amsellem with Piper Sandler. Your line is open.

David Amsellem — Piper Sandler & Co. — Analyst

Hey, thanks. Just a few. So first on AD, I apologize if I missed this. But is the FDA on board with the definition of mild-to-moderate per the body surface area being under 10%? I mean, is that something where there could be potential for daylight between you and the agency just — given me a refresher on that in terms of the mild-to-moderate definition? That’s number one. Number two is in liver disease, I guess the question here broadly is to the extent that you do show signal in Phase II, how wide of a population would you assess in a Phase III program?

Would it be Primary Biliary Cholangitis or something more broadly in patients with hepatic impairment? And then thirdly in notalgia paresthetica, just I guess maybe getting in — excuse here, but to the extent that you have a signal in that study — what does a Phase III program look like? Do you have to run two identical Phase III studies? I realize it’s new indications. So maybe just help us understand how you would think about that to the extent you move forward? Thanks.

Derek Chalmers — Chief Executive Officer, President, and Director

Yeah, thanks David. Three for you. That was well played. So on AD, yeah, the definition mild-to-moderate, BSA less than 10% is pretty much standard. On that they may add — put some IGA criteria to that, but that’s a standard definition for mild-to-moderate disease based on the extent of lesions in those patients. I don’t think that’s contentious based on what we see on other labels there. And as you know, it’s a standard regulatory path label-specific for mild-to-moderate patients. That’s not anything new for the agency.

So that’s that one. On liver disease, now PBC and I think we’ve had that discussion before — generally, the reason — you’re entirely correct that pruritus is broadly an issue across cholestatic liver diseases and a number of other liver related disorders. And the reason we went for PBC initially is the incidents there and the severity is certainly higher than in other liver diseases. Close to 70% there. So that we regarded as an important parameter for enrolling patients that we wanted consistency in a pruritus. We’ve lived this game long enough and patient reported outcome and one of the issues in control and placebo rates here is not the inconsistency and your pruritus response. So that was the reason to use PBC as of course an orphan indication, and that’s somewhat better — is a little bit and that is much more difficult to recruit and there are certain centers we’d like to get in there, which have been difficult to get to because of the COVID restrictions and that’s a pity.

But I think if we can push on here, we’re going to see an uptick in our patients there soon. And of course we have high confidence in the mechanism for kappa and that particular disease situations since we already knew that. Nalfurafine got that label extensions in Japan, you’ll recall after their initial label for hemodialysis associated pruritus. So we have high conviction that this is a mechanism that should be effective here. Ultimately running a Phase III program in PBC is unlikely for us. I think if we move into Phase III program and that will be a strategic decision when we get there in terms of what we’re seeing in these other patient populations is likely to be a broader liver disease population, so that we can actually run that program and then appropriate timeline.

So that’s the view on liver disease. We’re really PBC as a POC if you like as to efficacy in the liver disease situation. And it’s somewhat similar for notalgia paresthetica. Now, we think this is an interest and an indication per se with probably depending which estimates you want to believe in — probably around 1 million patients in the U.S. very common post aged 65 and really nothing available again for those patients. And I can tell you the entry scores we’re seeing in these patients coming into that trial are on the severe end of moderate-to-severe.

So this is a significant clinical issue for those patients. Again, we’re using that as we kind of a proof of concept patient group to cover the neuropathic edge area. It’s a large patient population estimated at some 8% of all the chronic pruritus in the U.S., so we wanted to make sure — again, we have a mechanism that’s going to be applicable for, if you like a nerve-related disorder that induces pruritus. So that’s — we’re using as our model population. Again, we’ll look at the ultimate data and decide whether we push forward here and to Phase III it’s actually been surprisingly rapid enrollment here, which probably speaks to the size of the patient population.

And again, if we look at this at the end of the day and it makes sense in terms of timeline to a label — that might be something we consider. But at this point, we’re interested in getting our first Phase III and it looks like it’s going to be in atopic dermatitis and then making sure confirming efficacy from all these other patient populations and then we’ll decide which of those makes sense to push forward into larger trials once we have all that data. Does that answer your question, David? It was fairly long, you fell asleep?

David Amsellem — Piper Sandler & Co. — Analyst

No, no, no, I’m here. I’m sorry, yeah, I was on mute. But yes, no, that’s very helpful.

Derek Chalmers — Chief Executive Officer, President, and Director

Okay. Thanks, David. Thanks for your questions.

Operator

[Operator Instructions] We have your next question from Jason Gerberry with Bank of America. Your line is open.

Jason Gerberry — Bank of America Merrill Lynch — Analyst

Hi guys. Thank you for taking my questions. I guess first question is, Derek, how do you envision the ramp of a drug like IV KORSUVA going in the first six months to a year in the dialysis setting? Sort of curious as you looked at other products in the setting like Parsabiv just sort of curious if you see a faster ramp or more cautious early slow trialing and then sort of a build up after the first 12 months? Just sort of curious, and I guess that had some implications for how the bundle could ultimately reset depending upon utilization and cost? And then my other question, there is some curiosity in the investment community about the potential impact of, I guess super responders within the KALM trials in lieu of the [Indecipherable] outcome and some other unfavorable FDA outcomes in the space. So, just curious if you can address that and your comfort level around those dynamics? Thanks.

Derek Chalmers — Chief Executive Officer, President, and Director

Thanks, Jason. Thanks for dialing in. So in terms of ramping KORSUVA Injection, I think we’ve had this kind of general discussion before. But it is an unusual market highly consolidated in the U.S. as you know with the vast majority of hemodialysis patients covered by two dialysis organizations, one of which we are aligned with and our corporate alliances [Indecipherable] the other being DaVita. So some 80% of U.S. trials are concentrated within those two dialysis organizations and clearly utility of the drug there and protocol adoption of the drug there is highly important to success ultimately, which is one of the reasons we decided to sign our initial agreement with Vifor Fresenius.

And as you know and recall from that — part of that agreement as we have a 50/50 profit split within Fresenius clinics. And you’re correct, looking at other drugs that have launched recently in that space, Parsabiv, of course been the only example of a drug through TDAPA. There is a rapid adoption there and we do see significant uptick in the first year and certainly two years. And as you know, that’s important for any drug in that space is that’s where we want to assess utility for future reimbursement post TDAPA.

So looking at, if you like, Vifor’s track record here with drugs such as Mircera in that space, they’ve certainly had great success with rapid uptake and I do think the uptake curve in this particular market space is going to look different than a standard PCP space. We do anticipate a faster ramp with KORSUVA Injection but good question, yet unusual market dynamics there. Then in terms of the dataset we’ve used in our NDA for efficacy confirmation. We’re very comfortable with that and certainly based on the interactions we’ve had with the FDA through now our late-cycle meeting. I don’t think we’re going to have any issues in relation to the dataset we’ve used there from both KALM-1 and KALM-2 for that submission.

Jason Gerberry — Bank of America Merrill Lynch — Analyst

Okay, thank you.

Derek Chalmers — Chief Executive Officer, President, and Director

Thanks, Jason.

Operator

We have your next question from Jack Padovano with Stifel. Your line is open.

Jack Padovano — Stifel Financial Corp. — Analyst

Hi, this is Jack. I’m calling in for Annabel Samimy. Thank you for taking our questions. So a few things related to the PDUFA date for IV KORSUVA set this month; what types of commercial activities are your partners pursuing at this time to prep for launch? And what priority will Vifor be positioning this in their portfolio? And what work has been done ahead of time of the PDUFA to file for the TDAPA payment from CMS? Is that something that can be done ahead of approval or not? And additionally, just for some clarification with the Phase III AD trial, what kind of options do you expect to propose to the FDA as far as design adjustment outside of just tailoring to the mild-to-moderate population? Do you feel like there are other modifications you can make to improve the statistics?

Derek Chalmers — Chief Executive Officer, President, and Director

Great, Jack. Thanks for the questions. Thanks for dialing in. So, let me — I think I got all of those, but let me start with the PDUFA. So, I think as I said on the call, we still expect PDUFA August 23. In terms of preparing for commercialization, as I said on the call, we will be assuming approval on August 23. We will actually be filing both our TDAPA and HCPCS applications the following month. So all that is in preparation of approval and will be underway that month. In terms of other commercial prep with Vifor and in combination with Vifor, they’ll be launching disease state awareness this quarter and actually into Q4 ahead of reimbursement.

We are constantly talking with CMS in terms of reimbursement post TDAPA and that’s been very productive and will continue. Vifor is working with large dialysis organizations, of course, some of them, they are very intimately related to and midsize dialysis organizations on optimizing formulary and protocol placement once we get KORSUVA Injection approval. You will see launch activities at the upcoming ASN Annual Meeting in November related to KORSUVA Injection and I certainly know that Vifor has rep training well underway and are planning for a launch meeting in January of 2022 so all of that has been ongoing.

Of course, prior to that, we had disease education directed from both the Cara MSL team and the Vifor MSL team so all that has been underway and continues to be underway in preparation for commercial launch. And then I think that covers your questions on KORSUVA Injection Jack but correct me if I’m wrong. And then your last question was Phase III trial design and how we see position of that within the patient population. And our view there and again is based on empirical data. And as I’ve said in our and our prepared remarks, we had known this was a heterogeneous population when we initiated that Phase II trial.

We pre-specified we were going to look at efficacy both in mild-to-moderate patients, which obviously have a different pathological presentation and actually different systemic immune profile than moderate-to-severe patients and it’s clear that we have a drug that shows its greatest efficacy in the mild-to-moderate population. So, we’ll also be presenting more data from that study a little later this year, which I think will help you in thinking about this, Jack, in terms of other endpoints, both quality of life and pathology endpoints that will be presented there. But we think we are very confident and where we think this drug works best and that’s in the mild-to-moderate patient population, which as you know is a defined patient population for labeling for the FDA. So that’s the positioning we’re going to propose when we meet with the agency.

Jack Padovano — Stifel Financial Corp. — Analyst

Great, thank you so much. That was very helpful.

Derek Chalmers — Chief Executive Officer, President, and Director

Thank you, Jack.

Operator

[Operator Instructions] We have your next question from Oren Livnat with H.C. Wainwright. Your line is open.

Oren Livnat — H.C. Wainwright & Co. — Analyst

Hi, I have a couple of questions around the Oral CKD pre-dialysis program. Can you just clear up some confusion I’m having on the Stage 5 versus earlier stage Phase III plan? I thought I recalled from last quarter that it was mainly an issue of how streamlined a program you could get away with, with regards to using IV KORSUVA safety data and the FDA essentially saying, by all means, you can go ahead and do that. But if you want to do that, you need to stick with Stage 5 and then you were going to try to convince them Stage 4 makes sense also because Stage 4 and 5 really are the same patient theoretically. Now, I’m hearing a little bit about incidents and disease burden questions. I’m wondering if these are part and parcel of the same issue or if I’m misunderstanding. And then just also on that same program, can you just remind us what have you told us that I might be forgetting about the Phase II program in terms of the population in that study. How much of that population was Stage 5 or Stage 4 to 5 and what differential efficacy did you see in that Phase II? Thanks.

Derek Chalmers — Chief Executive Officer, President, and Director

Thanks Oren and thanks for the question. So, yeah, no, you’re not misunderstanding on the Stage 5 and Stage 4 information we talked about last time. So the view or the data we talked about last time was it’s clear that Stage 5 is very similar to hemodialysis patients actually based on published data out there and epidemiology data. What’s not so clear and what we think is going to become clear as we’re looking at data that’s emerging from our studies is that Stage 4, particularly late Stage 4 patients and are very similar to Stage 5. In fact people don’t spend a lot of time in Stage 5.

A lot of Stage 4 patients may actually progress straight to hemodialysis. So we want to just firm that up, make sure we have all the statistics related to pruritus severity incidents in both Stage 4 and Stage 5. In other words, confirm that both Stage 4 and 5 are very similar to hemodialysis patients, which is the argument we’ve made initially and therefore the same if you like recommendation should apply that we should be able to reference all the data we generated with KORSUVA Injection in hemodialysis patients. As you know we have a significant number of safety exposures there really exposure levels that exceed those we see with oral. And also maybe a possibility of reference in the efficacy data related to both late Stage 4 and Stage 5.

That’s the exercise we have underway right now is gathering that information and then re-reengaging with the agency in the coming months to present that data and indicate that, really, yes, it’s true that late Stage and Stage 5 look very similar to hemodialysis but so based on the data we’re generating so do late Stage 4 patients and therefore it would make sense to include them in any Phase III program and I think we talked about this last time and really from a logistical standpoint to run that Phase III program across an efficacy period only with Stage 5 would risk losing very many patients to hemodialysis. So that’s another part of the debate or discussion we’ll be having with the FDA once we have that dataset. And then I’ve forgotten what your second question was, Oren.

Oren Livnat — H.C. Wainwright & Co. — Analyst

Yeah, the second question was just, if you could remind us, I can’t remember if you’ve told us before and I just forgot in the Oral pre-CKD the Stage 3 to 5 Phase II, what was the representation in that study and what efficacy do you see across the difference studies?

Derek Chalmers — Chief Executive Officer, President, and Director

Yeah. So you’re right, that was a trial that encompassed all pre-dialysis CKD subgroups from 3A to 3B, 4 and 5. Approximately 50% of the patients in that study were 3A and 3B. But as you know — majority of patients are there in the population. And then, the rest was Stage 4 and Stage 5. In terms of efficacy, that is KORSUVA response is somewhat similar across these stages in terms of drug response. What differs between the early stage and the late stage is that we see a higher placebo rate in early stage CKD patients versus Stage 4 and Stage 5.

And that’s probably because those early stage patients have more labile pruritus response earlier in the disease process. They don’t have consistent a response. So one benefit, if you like for us moving into Phase III and de-risking that Phase III program because as you’re well aware, one of the main issues with patient reported outcomes is controlling that placebo rate. Moving to Stage 4 and 5 is actually going to be beneficial for us in our late-stage program and that we should be minimizing aberrant placebo responses by focusing on the patient group, subgroups that have the highest and most consistent pruritic responses.

Oren Livnat — H.C. Wainwright & Co. — Analyst

Okay. And I apologize, if I could just get clarification on your previous answer about determining how similar Stage 4 and 5 pre-dialysis patients are to dialysis. Do you mean in terms of their perception and severity of their pruritus or do you mean in terms of the actual pathology and the health of those patients so that for relevance in terms of mechanism of action from the IV study and whether we should apply to the same?

Derek Chalmers — Chief Executive Officer, President, and Director

Yeah. No, it’s actually a bit of both, but we are most interested in the pruritus severity and incidents between those two groups. And as you know, as a continuum for these patients so when we look at the data that’s out there and the data we are generating it’s certainly clear that very late Stage 4 are very similar to Stage 5. And as you know that pathology difference is slight right for late-Stage 4 to 5. So that’s the data we’re generating and we’re going to use that in our discussion.

Oren Livnat — H.C. Wainwright & Co. — Analyst

Okay. Well, I apologize for asking so many questions. Thanks so much. Good luck.

Derek Chalmers — Chief Executive Officer, President, and Director

No, no problem. Thanks for the question, Oren.

Operator

[Operator Instructions] I’m showing no further questions at this time. I would now like to turn it back to the Cara team for any closing remarks.

Derek Chalmers — Chief Executive Officer, President, and Director

Okay. Thank you, operator and thank you everybody for participating in today’s call. I’d also like to thank the entire Cara team, our study investigators and most importantly, all of the patients to continue to participate in our clinical trials. So we look forward to updating you again actually very, very soon. And thanks again for dialing in. Have a good rest of the day.

Operator

[Operator Closing Remarks]